Wu Xi, Fang Nana, Liang Ziteng, Nie Jianhui, Lang Sen, Fan Changfa, Liang Chunnan, Huang Weijin, Wang Youchun
Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China.
National Vaccine and Serum Institute, Beijing 101111, China.
Vaccines (Basel). 2023 Jun 22;11(7):1133. doi: 10.3390/vaccines11071133.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains widely pandemic around the world. Animal models that are sensitive to the virus are therefore urgently needed to evaluate potential vaccines and antiviral agents; however, SARS-CoV-2 requires biosafety level 3 containment. To overcome this, we developed an animal model using the intranasal administration of SARS-CoV-2 pseudovirus. As the pseudovirus contains the firefly luciferase reporter gene, infected tissues and the viral load could be monitored by in vivo bioluminescent imaging. We used the model to evaluate the protective efficacy of monoclonal antibodies and the tissue tropism of different variants. The model may also be a useful tool for the safe and convenient preliminary evaluation of the protective efficacy of vaccine candidates against SARS-CoV-2, as well as the treatment efficacy of anti-viral drugs.
2019冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,在全球范围内仍广泛流行。因此,迫切需要对该病毒敏感的动物模型来评估潜在疫苗和抗病毒药物;然而,SARS-CoV-2需要生物安全3级防护。为克服这一问题,我们开发了一种通过鼻内接种SARS-CoV-2假病毒的动物模型。由于假病毒含有萤火虫荧光素酶报告基因,可通过体内生物发光成像监测感染组织和病毒载量。我们使用该模型评估单克隆抗体的保护效力以及不同变体的组织嗜性。该模型也可能是一个有用的工具,用于安全、方便地初步评估候选疫苗对SARS-CoV-2的保护效力以及抗病毒药物的治疗效果。